Search Result

Results for "

opioid antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Opioid Receptor (89) 5-HT Receptor (3) Adrenergic Receptor (3) Amino Acid Derivatives (1) Dopamine Receptor (4) Drug Metabolite (1) Flavivirus (1) Fluorescent Dye (2) GABA Receptor (1) GlyT (2) iGluR (2) Isotope-Labeled Compounds (3) Leukotriene Receptor (1) mAChR (1) Neuropeptide FF Receptor (2) P2X Receptor (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (2) Sigma Receptor (4) TRP Channel (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Endocrinology (3) Infection (2) Inflammation/Immunology (9) Metabolic Disease (6) Neurological Disease (95)

By Targets:

Opioid Receptor (89)

5-HT Receptor (3)

Adrenergic Receptor (3)

Amino Acid Derivatives (1)

Dopamine Receptor (4)

Drug Metabolite (1)

Flavivirus (1)

Fluorescent Dye (2)

GABA Receptor (1)

GlyT (2)

iGluR (2)

Isotope-Labeled Compounds (3)

Leukotriene Receptor (1)

mAChR (1)

Neuropeptide FF Receptor (2)

P2X Receptor (2)

Platelet-activating Factor Receptor (PAFR) (1)

Potassium Channel (2)

Sigma Receptor (4)

TRP Channel (2)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (9)

Metabolic Disease (6)

Neurological Disease (95)

114

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Opioid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107744

Nalmefene	Opioid Receptor	Neurological Disease
Nalmefene is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene is used for opioid overdose and alcohol dependence .

HY-163895

*δ opioid* receptor antagonist 1**	Fluorescent Dye Opioid Receptor	Neurological Disease
δ opioid receptor antagonist 1 (compound 6-Cy3) is a fluorescent antagonist probe with high selectivity for δ opioid receptor (DOR) (K_i=1.7 nM). δ opioid receptor antagonist 1 can be used to study the mechanism of pain perception .

HY-144609

*Mu opioid* receptor antagonist 4**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 4 (compound 31) is a potent and selective *μ opioid* receptor (MOR)** antagonist with a K_i of 0.38 nM and an EC₅₀ of 1.07 nM. Mu opioid receptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 4 Mu opioid receptor antagonist 4 can be used for researching opioid use disorders (OUD) .

HY-155320

*Mu opioid* receptor antagonist 7**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 7 (compound 24) is a potent and CNS permeable antagonist of *µOR (µ-opioid* receptor), with an IC₅₀** of 29 ± 3.0 nM. Mu opioid receptor antagonist 7 can be used for the research of pain and opioid use disorder .

HY-162669

*Mu opioid* receptor antagonist 8**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 8 (368) is a *μ-opioid* receptor** antagonist. Mu opioid receptor antagonist 8 (368) significantly inhibits met-enkephalin-induced µOR activation of G_i .

HY-144608

*Mu opioid* receptor antagonist 3**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 3 (compound 26) is a potent and selective *μ opioid* receptor (MOR)** antagonist with a K_i of 0.24 nM and an EC₅₀ of 0.54 nM. Mu opioid receptor antagonist 3 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 3 can be used for researching opioid use disorders (OUD) .

HY-144610

*Mu opioid* receptor antagonist 5**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 5 (compound NAP) is a selective and blood-brain barrier (BBB) penetrant *μ opioid* receptor (MOR)** antagonist with an EC₅₀ value of 1.14 nM and a K_i value of 0.37 nM. Mu opioid receptor antagonist 5 can be used for researching opioid use disorders (OUD) .

HY-144607

*Mu opioid* receptor antagonist 2**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant *μ opioid* receptor (MOR)** antagonist with a K_i of 0.37 nM and an EC₅₀ of 0.44 nM. Mu opioid receptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 2 can be used for researching opioid use disorders (OUD) .

HY-144606

*Mu opioid* receptor antagonist 1**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active *μ opioid* receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀** of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-101306

Clocinnamox mesylate	Opioid Receptor	Neurological Disease
Clocinnamox (mesylate) is a potent **opioid antagonist** acting at mu, kappa and delta-receptors. Clocinnamox is a selective mu-receptor antagonist than kappa and delta-receptors .

HY-120277

TIPP H-Tyr-Tic-Phe-Phe-OH	Opioid Receptor	Neurological Disease
TIPP is a potent and selective δ-opioid antagonist with a K_i value of 1.22 nM .

HY-D1387

Naloxone fluorescein acetate	Fluorescent Dye	Neurological Disease
Naloxone fluorescein acetate is the fluorescent-derivative of Naloxone. Naloxone is an opioid antagonist. Naloxone is the antidote for reversing the effects of an opioid overdose .

HY-17417A

Naloxone	Opioid Receptor	Neurological Disease
Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias .

HY-147560

σ1 Receptor/μ Opioid receptor modulator 1	Sigma Receptor Opioid Receptor	Neurological Disease
σ1 Receptor/μ Opioid receptor modulator 1 (Compound 44) is a potent σ1 receptor antagonist and *μ opioid* receptor** agonist with K_is of 1.86 nM and 2.1 nM, respectively.σ1 Receptor/μ Opioid receptor modulator 1 exhibits potent analgesic activity. σ1 Receptor/μ Opioid receptor modulator 1 can be used for the research of neuropathic pain .

HY-123689A

Samidorphan hydrochloride ALKS-33 hydrochloride; RDC-0313 hydrochloride	Opioid Receptor	Neurological Disease
Samidorphan hydrochloride is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan hydrochloride acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan hydrochloride primarily acts as an opioid receptor antagonist in vivo .

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-123689S

Samidorphan-d4 ALKS-33-d₄; RDC-0313-d₄	Isotope-Labeled Compounds	Neurological Disease
Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-123689S1

Samidorphan-d5 ALKS-33-d₅; RDC-0313-d₅	Isotope-Labeled Compounds	Neurological Disease
Samidorphan-d5 (ALKS-33-d5) is a tritiated version of Samidorphan. Samidorphan is an orally active *opioid* system modulator that binds with high affinity to *μ-opioid, κ-opioid, and δ-opioid* receptors. Samidorphan is a *μ-opioid* receptor antagonist and a partial agonist at *k-opioid* and *δ-opioid* receptors. Samidorphan acts primarily as an *opioid* receptor antagonist in vivo .

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic *κ3-opioid* receptor** agonist, and a partial agonist at the cloned μ and *δ opioid* receptors*, and an antagonist* at opioid-like NOP receptors. Naloxone benzoylhydrazone has potently analgesia effect .

HY-10486

JDTic	Opioid Receptor	Neurological Disease
JDTic is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease
Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-120927

Alvimopan metabolite	Others	Neurological Disease
Alvimopan metabolite is a μ opioid receptor antagonist with activity that selectively interacts with μ peripheral receptors. Alvimopan metabolite can be used as a potential inhibitory drug to alleviate the side effects caused by opioids. Alvimopan metabolite was identified as a highly selective μ opioid receptor antagonist during research and development .

HY-107748A

5'-Guanidinonaltrindole TFA 5'-GNTI TFA	Others	Neurological Disease
5'-Guanidinonaltrindole TFA is a selective kappa-opioid receptor antagonist with significant opioid antagonist activity. 5'-Guanidinonaltrindole TFA exhibits 5 times the antagonistic potency of the prototypical kappa-opioid receptor antagonist norbinatorphimine in smooth muscle preparations, with a selectivity ratio exceeding 500 times. Binding and functional studies of 5'-Guanidinonaltrindole TFA showed pA(2) values comparable to smooth muscle data. 5'-Guanidinonaltrindole TFA is regarded as a potentially valuable pharmacological tool for studying opioids due to its high selectivity and potency .

HY-100903

Norbinaltorphimine dihydrochloride 4 Publications Verification nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride	Opioid Receptor	Neurological Disease
Norbinaltorphimine dihydrochloride is a potent and selective *κ opioid* receptor** antagonist.

HY-156614

Icalcaprant	Opioid Receptor	Neurological Disease
Icalcaprant is a kappa-opioid receptor antagonist .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Neurological Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a *μ-opioid-receptor* antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-112263

ORL1 antagonist 1	Opioid Receptor	Neurological Disease Metabolic Disease
ORL1 antagonist 1 is an opioid receptor-like 1 (ORL1) antagonist with an IC₅₀ of 61 nM.

HY-17417

Naloxone hydrochloride 2 Publications Verification	Opioid Receptor	Neurological Disease
Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .

HY-100122

Bevenopran 1 Publications Verification CB-5945; ADL-5945	Opioid Receptor	Neurological Disease
Bevenopran is a peripheral *μ-opioid* receptor** antagonist .

HY-107748

5'-Guanidinonaltrindole hydrochloride 5'-GNTI hydrochloride	Opioid Receptor	Neurological Disease
5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent *κ-opioid* receptor** antagonist with a K_i of 0.18 nM for human κ-opioid receptor .

HY-A0118AS

Naloxegol-d5 oxalate	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

HY-17417AS

Naloxone-d5	Opioid Receptor	Others
Naloxone D5 is deuterium labeled Naloxone. Naloxone is a a potent opioid receptor antagonist.

HY-101376

(+)-N-Allylnormetazocine hydrochloride (+)-SKF 10047 hydrochloride; (+)-N-Allyl-N-normetazocine hydrochloride	Opioid Receptor	Neurological Disease
(+)-N-Allylnormetazocine ((+)-SKF 10047) hydrochloride is a benzomorphan opioid with psychotomi metic effects. (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist with K_i values of 300 nM and 27 μM for σ1 and σ2 opioid receptors, respectively. (+)-N-Allylnormetazocine hydrochloride can be used for the research of neurological disease .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a *delta-opioid* receptor** antagonist and can be used for seizure research.

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective *δ opioid* receptor (DOR)** peptide antagonist .

HY-101718

Aticaprant 5 Publications Verification CERC-501; LY-2456302	Opioid Receptor	Neurological Disease
Aticaprant (CERC-501) is a potent and centrally-penetrant kappa opioid receptor antagonist with a K_i of 0.807 nM.

HY-107749

ML 190	Opioid Receptor	Neurological Disease
ML 190 is a selective *κ opioid* receptor (KOR)** antagonist with an IC₅₀ of 120 nM and an EC₅₀ of 129 nM, respectively .

HY-158236

ORL1 antagonist 2	Opioid Receptor	Neurological Disease
ORL1 antagonist 2 (1B) is an opioid receptor-Like 1 (ORL1) antagonist, usd in P-glycoprotein (P-gp) research .

HY-106732

AT-076	Opioid Receptor	Neurological Disease
AT-076 is an opioid pan antagonist at nociception, kappa, mu, and delta opioid receptors, with K_i values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively .

HY-123142

RX809055AX	Opioid Receptor	Neurological Disease
RX 809055AX is a potent long lasting *opioid* antagonist with selectivity towards at mu and delta receptors .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a *delta-opioid* receptor** antagonist. Diallyl G shows inhibitory effect on GTPase .

HY-17417R

Naloxone hydrochloride (Standard)	Opioid Receptor	Neurological Disease Cancer
Naloxone (hydrochloride) (Standard) is the analytical standard of Naloxone (hydrochloride). This product is intended for research and analytical applications. Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .

HY-107750A

Cyprodime hydrochloride	Opioid Receptor	Neurological Disease
Cyprodime hydrochloride is a highly selective *μ-opioid* receptor** antagonist with K_i values of 5.4 nM, 244.6 nM and 2187 nM for μ-, δ- and κ-opioid receptors, respectively. Cyprodime hydrochloride has anti-depressant-like effect .

HY-133717

Naltriben	Opioid Receptor TRP Channel	Cancer
Naltriben is a selective *δ2-opioid* receptor** antagonist and TRPM7 activator. Naltriben enhances glioblastoma cell migration and invasion. Naltriben can be used in research into neurological diseases and cancer .

HY-117881

CJ-15208	Others	Neurological Disease
CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics .

HY-117040

nor-Binaltorphimine 4 Publications Verification Norbinaltorphimine; NorBNI	Opioid Receptor	Others
nor-Binaltorphimine is a selective antagonist of *kappa-opioid* receptor**. nor-Binaltorphimine has a long-lasting effect in vivo .

HY-108229

6β-Naltrexol 6β-Hydroxynaltrexone	Drug Metabolite Opioid Receptor	Neurological Disease
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective *opioid* antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-P10177

Acetalin-3	Opioid Receptor	Neurological Disease
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10175

Acetalin-1	Opioid Receptor	Neurological Disease
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-118615

LY2048978	Opioid Receptor	Neurological Disease
LY2048978 is a non-selective opioid receptor antagonist with K_i of 0.287, 0.471 and 1.05 nM for human mu, kappa and delta opioid receptors in vitro, respectively. LY2048978 can be used in the research of major depressive disorder and alcohol use disorder .

Cat. No.	Product Name	Type

HY-D1387

Naloxone fluorescein acetate	Fluorescent Dyes/Probes
Naloxone fluorescein acetate is the fluorescent-derivative of Naloxone. Naloxone is an opioid antagonist. Naloxone is the antidote for reversing the effects of an opioid overdose .

Cat. No.	Product Name	Target	Research Area

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective *δ opioid* receptor (DOR)** peptide antagonist .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a *delta-opioid* receptor** antagonist. Diallyl G shows inhibitory effect on GTPase .

HY-P10177

Acetalin-3	Opioid Receptor	Neurological Disease
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10175

Acetalin-1	Opioid Receptor	Neurological Disease
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10394

DP32	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .

HY-P10395

DP50	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .

HY-W013154

Fmoc-Tic-OH	Amino Acid Derivatives	Others
Fmoc-Tic-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as the biotinylated derivative of the opioid receptor antagonist TIPP .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant *μ opioid* receptor** antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P2052

AWL 60	Peptides	Others
AWL 60 is a compound with SP antagonist and weak opioid agonist properties, which can antagonize SP-agonists in vitro and attenuate the decrease in blood pressure caused by SP-agonists in vivo.

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an *opioid* antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant *μ opioid* receptor** antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective *μ-opioid* receptor** antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P2429

N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu	Peptides	Others
N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen?] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective *μ-opioid* receptor** antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect .

HY-P3839

Nocistatin	Opioid Receptor	Neurological Disease
Nocistatin, a neuropeptide, is an endogenous ligand for the *orphan opioid* receptor-like receptor*. Nocistatin is also a functional antagonist* of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a G_i/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0193

Prazosin 10+ Cited Publications	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Prazosin is an α-adrenergic receptor antagonist. Prazosin can reduce inflammation, relieve anxiety, alleviate panic, prevent memory decline, and modulate the pain-relieving effects of opioids. Prazosin can be used in the study of hypertension and Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is a tritiated version of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .